A significant correlation between MC1R variants and worse outcomes (overall response rate and progression-free survival) in BRAF-mutated metastatic melanoma patients treated with target therapy was observed, due to the interactions of MC1R with other pathways [216]. This evidence concerns the gene MC1R and metastatic melanoma.